TITLE

Therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients

AUTHOR(S)
Kay, Marsha H.; Wyllie, Robert
PUB. DATE
July 1995
SOURCE
Clinical Pediatrics;Jul1995, Vol. 34 Issue 7, p372
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients. Production of alpha interferons; Different types of hepatitis; Treatment recommendations.
ACCESSION #
9507300336

 

Related Articles

  • Lamivudine: A Viewpoint by Nancy Leung. Leung, N. // Pediatric Drugs;2002, Vol. 4 Issue 10, p695 

    Discusses the advances in therapy for chronic hepatitis B infection. Background on interferon and lamivudine therapies approved by the U.S. Food and Drug Administration; Results of clinical trials in adults with chronic hepatitis B; Information on the treatment dilemma that occurs in adult and...

  • Use high-dose, long-term interferon for chronic non-A, non-B hepatitis.  // Formulary;Sep95, Vol. 30 Issue 9, p544 

    Presents an abstract of the article `A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis,' by T. Poynard, P. Bedossa, M. Chevallier et al, which appeared in the 1995 issue of `The New England Journal of Medicine' periodical.

  • Peginterferon-α-2a the dominant strategy for CHC.  // PharmacoEconomics & Outcomes News;11/27/2010, Issue 617, p10 

    The article presents two studies, which examined the cost effectiveness of peginterferon-α-2a (PEG-IFN-α-2a) combined with ribavirin in the treatment of chronic hepatitis in Spain and Mexico.

  • Chronic non-A, non-B hepatitis: Use high-dose, long-term interferon.  // Modern Medicine;Oct95, Vol. 63 Issue 10, p57 

    Presents an abstract of the article `A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis,' by T. Poynard, P. Bedossa, M. Chevallier, et al from the `New England Journal of Medicine' dated June 1, 1995.

  • Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option? Rekha Cheruvattath; Marianne Rosati; Manjushree Gautam; Hugo Vargas; Jorge Rakela // Digestive Diseases & Sciences;Mar2007, Vol. 52 Issue 3, p732 

    Abstract??Currently, there are limited therapeutic options available for chronic hepatitis C (HCV) patients who fail treatment with peginterferon ? (PEG IFN) + ribavirin (RBV). An option is retreatment with a second course PEG-IFN + RBV. However, the virologic clearance with this option is...

  • Long-Term Results of Interferon Alpha Monotherapy in Patients with HBeAg-Negative Chronic Hepatitis B. Sabahattin Kaymakoglu; Ahmet Danalioglu; Kadir Demir; Cetin Karaca; Filiz Akyuz; Derya Onel; Selim Badur; Ugur Cevikbas; Fatih Besisik; Yilmaz Cakaloglu; Atilla Okten // Digestive Diseases & Sciences;Mar2007, Vol. 52 Issue 3, p727 

    Abstract??We sought to evaluate the long-term results of interferon-? (IFN-?) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Eighty HBeAg-negative naive patients (62 men; mean age, 39.9?years) who received IFN-? for 6 months were studied. Alanine...

  • Treatment of hepatitis C with telaprevir. Alberti, Alfredo; Piovesan, Sara // Hot Topics in Viral Hepatitis;2013, Vol. 9 Issue 29, p7 

    Until 2011 the standard of care in the treatment of hepatitis C virus (HCV) infection consisted of dual-combination pegylated interferon-a and ribavirin administered for 24 or 48 weeks, depending on the viral genotype and on the early virological response. Now, a triple therapy based on the...

  • The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Nunnari, G.; Montineri, A.; Portelli, V.; Savalli, F.; Fatuzzo, F.; Cacopardo, B. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 8, p1013 

    BACKGROUND, Acute hepatitis C becomes chronic in 50% of cases. Early treatment seems to be effective in eradicating HCV infection, although no clear recommendations are available in terms of time of initiation, regimen and duration of therapy. We report a retrospective review of 48 patients with...

  • Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. Dill, Michael T.; Makowska, Zuzanna; Trincucci, Gala; Gruber, Andreas J.; Vogt, Julia E.; Filipowicz, Magdalena; Calabrese, Diego; Krol, Ilona; Lau, Daryl T.; Terracciano, Luigi; van Nimwegen, Erik; Roth, Volker; Heim, Markus H. // Journal of Clinical Investigation;Apr2014, Vol. 124 Issue 4, p1568 

    The use of pegylated interferon-α (pegIFN-α) has replaced unmodified recombinant IFN-α for the treatment of chronic viral hepatitis. While the superior antiviral efficacy of pegIFN-α is generally attributed to improved pharmacokinetic properties, the pharmacodynamic effects of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics